Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejectionbenzinga_article·1 hour agoOTLK-18.15%
This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Mondaybenzinga_article·4 hours agoF-C+0.26%F-D-0.14%
Pre-market hot trades in US stocks: Outlook Therapeutics up 8.84% in pre-market; SAP up 4.80% in pre-marketPrice Alert·5 hours agoOTLK-18.15%SAP+7.68%
FDA Approvals and Earnings Beats Propel Specialized US-Listed FirmsGlobal Report·1 day ago, 04:14 AMREPL-11.44%CELC+0.91%
Niche U.S. Equities Face Commercial and Regulatory Tests in Mid-2026Global Report·2 days ago, 04:18 AMAUR+1.85%VSME+5.60%
From Web3 Pivots to AI Robotics Deals: Tracking Capital Shakeups Across U.S. EquitiesGlobal Report·2 days ago, 04:13 AMOTLK-18.15%YYAI-71.13%
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD | OTLK Stock NewsStockTitan·Jul 24 at 05:40 AMOTLK-18.15%
Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. KenyonTradingView·Jul 24 at 05:03 AMOTLK-18.15%
